Mission.
Medikine, Inc. is a privately-held, seed-stage biotech company with the mission of discovering agonists (i.e., activators) of clinically relevant cytokine receptors. Inhibition of cytokine receptor activity has led to some of the most valuable pharmaceutical products of the last three decades – e.g. Humira and Enbrel for rheumatoid arthritis, and Avastin and Herceptin for cancer. Development of activators of cytokine receptors has proven more difficult, and many product opportunities with potentially significant clinical benefit remain unrealized. Medikine is utilizing a proprietary technology to identify a novel class of cytokine receptor agonists that are based on low molecular weight peptides, unrelated in sequence to the natural cytokine proteins, which can be engineered to have distinct advantages over the natural cytokines.
Contact Us.
info@medikine.com
1455 Adams Dr., Suite 1180
Menlo Park, CA 94025
USA